MedDataX Logo

Endothelin-Receptor Blockade in Coronary Heart Disease

NCT ID: NCT00427232

Last Updated: 2007-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-05-31

Study Completion Date

2006-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endothelin is a hormon that causes acute and chronic narrowing of heart vessels. The purpose of this study is to assess whether suppression of this activity by using two types of receptor antagonists can reduce this effect and thus improve blood supply of the heart muscle.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Endothelin (ET) is the most potent vasoconstrictor known and plays a major role in the development of coronary artery disease as well as in acute vasoconstriction. This effect is mainly mediated by the vascular ET-A receptor, whereas the ET-B receptor mediates vasodilation and cleavage of ET. Currently, there are both selective ET-A antagonists and non-selective ET-A and ET-B antagonists under investigation. The aim of the study is to test the effect of ET-receptor blockade on the vasoreagibility of epicardial and intramyocardial coronary arteries in patients undergoing cardiac catheterization. We randomly use the selective ET-A receptor BQ-123 (Group A) and the combination of BQ-123 and the ET-B receptor antagonist BQ-788 (Group B). The tested infusion will be applied selectively into the assessed coronary artery by a special infusion catheter. To evaluate the morphometric changes we use quantitative coronary angiography to measure the diameter of the coronary artery before and after intracoronary infusion of the tested substances. Furthermore we will use Pressure Wire to measure the hemodynamic conditions before and after infusion, thus evaluating the epicardial and the intramyocardial blood perfusion.

Comparison: Coronary artery diameter as measured by quantitative angiography (minimal lumen diameter) and parameters indicative of epicardial and intramyocardial blood flow as determined by Pressure Wire (fractional flow reserver, coronary flow reserve, intramyocardial resistance) before and after ET-antagonist infusion will be compared.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Vessels Endothelins Vascular Resistance

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

coronary heart disease endothelins coronary angiography blood flow velocity fractional flow reserve, myocardial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BQ-123 and BQ-788

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* coronary artey disease
* stable angina pectoris
* male and post-menopausal female patients
* age above 19 years
* able and willing to conform to the requirements of the study
* provided written informed consent

Exclusion Criteria

* severe focal coronary stenosis
* visually calcified stenosis
* aorto-ostial lesion location and unprotected left main stenosis
* pre-menopausal female patients
* diabetes mellitus
* unstable angina pectoris and/or acute Q-wave myocardial infarctaion within the past 72 hours
* current vasoactive medication
* previous percutaneous transluminal revascularization at the site of the target lesion
* lesion which has extremely angulated segments \>90%
* vessel with escessive tortuosity of the proximal segment
* severe hypotension
* severely reduced left ventricular function
* severe carotid stenosis
* patients with pace maker
* patients with elevated liver enzymes
* patients simultaneously participating in another device or drug study
* inability of unwillingness to comply with the study protocol
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Vienna

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Neunteufl, MD

Role: PRINCIPAL_INVESTIGATOR

Dept. of Internal Medicine II, Medical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept. of Internal Medicine II, Medical University of Vienna

Vienna, Vienna, Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

References

Explore related publications, articles, or registry entries linked to this study.

Wexberg P, Sperker W, Morgenthaler NG, Heinzl H, Adlbrecht C, Plass C, Glogar HD, Lang IM, Neunteufl T. Inhomogeneous vasomotor effects of moderate selective and non-selective endothelin-receptor blockade in stable coronary artery disease. Heart. 2009 Aug;95(15):1258-64. doi: 10.1136/hrt.2008.158550. Epub 2009 May 3.

Reference Type DERIVED
PMID: 19414437 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EK 242/2002

Identifier Type: -

Identifier Source: org_study_id